Skip to main content
SpringerLink
Log in

Sexual Dysfunction in Male Patients with Hypertension

Influence of Antihypertensive Drugs

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Evidence suggests that arterial hypertension, in addition to being a cardiovascular and renal risk factor, may also be associated with an impairment of male sexual function. Since other cardiovascular risk factors, especially diabetes mellitus, have also been shown to correlate with impaired sexual function it has been proposed that sexual and especially erectile dysfunction may, at least in part, represent just another manifestation of atherosclerotic vascular disease.

In addition to hypertension itself, sexual function in male hypertensive patients may also be affected by antihypertensive drug treatment. Available evidence suggests that centrally acting sympatholytic agents, β-adrenoceptor antagonists (β-blockers) and diuretics may have the potential to further impair sexual function. Calcium channel antagonists and ACE inhibitors may be neutral with respect to this endpoint. Preliminary data from several randomised and open studies have suggested that angiotensin II (AT)1-receptor antagonists may even be associated with an improvement of sexual function.

However, many aspects of the interaction between hypertension, antihypertensive drug treatment and male sexual function remain unclear. Among other factors, the relative contribution of disease labelling both to the higher incidence of sexual dysfunction in hypertensive versus normotensive males and to the negative impact of treatment remains an open question. Furthermore, dose dependence of the observed effects of antihypertensive agents on sexual function, the role of combination therapy and the anticipation of proposed adverse effects of treatment are unresolved issues. Thus, more data from studies of high quality using standardised definitions and procedures are urgently needed to at least partially resolve some of the many open questions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chobanian AV, Bakris GL, Black HR, et al., on behalf of the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206–52

    Article  PubMed  CAS  Google Scholar 

  2. Staessen JA, Wang J. Blood pressure lowering for the secondary prevention of stroke. Lancet 2001; 358: 1026–7

    Article  PubMed  CAS  Google Scholar 

  3. Di Bari M, Pahor M, Franse LV, et al. Dementia and disability outcomes in large hypertension trials: lessons learned from the Systolic Hypertension in the Elderly Program (SHEP) trial. Am J Epidemiol 2001; 153: 72–8

    Article  PubMed  Google Scholar 

  4. Swan GE, De Carli C, Miller BL, et al. Association of midlife blood pressure to late-life cognitive decline and brain morphology. Neurology 1998; 51: 986–93

    Article  PubMed  CAS  Google Scholar 

  5. Glynn RJ, Beckett LA, Hebert LE, et al. Current and remote blood pressure and cognitive decline. JAMA 1999; 281: 438–45

    Article  PubMed  CAS  Google Scholar 

  6. Sacktor N, Gray S, Kawas C, et al. Systolic blood pressure within an intermediate range may reduce memory loss in an elderly hypertensive cohort. J Geriatr Psychiatry Neurol 1999; 12: 1–6

    Article  PubMed  CAS  Google Scholar 

  7. Kivipelto M, Helkala EL, Hanninen T, et al. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 2001; 56: 1683–9

    Article  PubMed  CAS  Google Scholar 

  8. Feldmann HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychological correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54–61

    Google Scholar 

  9. Bacon CG, Mittleman MA, Kawachi I, et al. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med 2003; 139: 161–8

    PubMed  Google Scholar 

  10. Düsing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Pressure 2003; 12 Suppl. 2: 29–34

    Article  Google Scholar 

  11. Fogari R, Zoppi A. Effect of antihypertensive therapy on sexual activity in hypertensive men. Curr Hypertens Report 2002; 4: 202–10

    Article  Google Scholar 

  12. NIH Consensus Development Panel on Impotence. Impotence. JAMA 1993; 270: 83–90

    Article  Google Scholar 

  13. Kinsey AC, Pomeroy W, Martin CE. Age and sexual outlet. In: Kinsey AC, Pomeroy W, Martin CE, editors. Sexual behaviour in the human man. Philadelphia (PA): WB Saunders, 1948: 218–62

    Google Scholar 

  14. Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impotence Res 2000; 12: 305–11

    Article  CAS  Google Scholar 

  15. Blanker MH, Bosch JL, Groeneveld FP, et al. Erectile and ejaculatory dysfunction in a community-based sample of men 50–78 years old: prevalence, concern, and relation to sexual activity. Urology 2001; 57: 763–8

    Article  PubMed  CAS  Google Scholar 

  16. Ansong KS, Lewis C, Jenkins P, et al. Epidemiology of erectile dysfunction: a community-based study in rural New York. Ann Epidemiol 2000; 10: 293–6

    Article  PubMed  CAS  Google Scholar 

  17. Parazzini F, Menchini Fabris F, Bortolotti A, et al. Frequency and determinants of erectile dysfunction in Italy. Eur J Urol 2000; 37: 43–9

    Article  CAS  Google Scholar 

  18. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment and control of hypertension in the United States, 1988–2000. JAMA 2003; 290: 199–206

    Article  PubMed  Google Scholar 

  19. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995; 25: 305–13

    Article  PubMed  CAS  Google Scholar 

  20. Franklin SS, Gustin W, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure: the Framingham Heart Study. Circulation 1997; 96: 308–15

    Article  PubMed  CAS  Google Scholar 

  21. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003 21: 1011–1053

    Article  Google Scholar 

  22. World Health Organization(WHO)/International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension statement on management of hypertension. J Hypertens 2003; 21: 1983–92

    Article  Google Scholar 

  23. Grimm RH Jr, Grandits GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women: Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997; 29: 8–14

    Article  PubMed  CAS  Google Scholar 

  24. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo: the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328: 914–21

    CAS  Google Scholar 

  25. Delia Chiesa A, Pfifner D, Meier B, et al. Sexual activity in hypertensive men. J Human Hypertens 2003; 17: 515–21

    Article  Google Scholar 

  26. Fogari R, Zoppi A, Poletti L, et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 2001; 14: 27–31

    Article  PubMed  CAS  Google Scholar 

  27. Feldman HA, Johannes CB, Derby CA, et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med 2000; 30: 328–38

    Article  PubMed  CAS  Google Scholar 

  28. Madersbacher S, Temmel C, Racz U, et al. Prevalence and risk factors for erectile dysfunction in Austria: analysis of a health screening project. Wien Klin Wochenschr 2003; 115: 822–30

    Article  PubMed  Google Scholar 

  29. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–30

    Article  PubMed  CAS  Google Scholar 

  30. Akkus E, Kodioglu A, Esen A, et al., on behalf of the Turkish Erectile Dysfunction Prevalence Study Group. Prevalence and correlates of erectile dysfunction in Turkey: a populationbased study. Eur Urol 2002; 41: 298–304

    Article  PubMed  Google Scholar 

  31. Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I, et al. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfunction Erectil Masculina Study. J Urol 2001; 166: 569–74

    Article  PubMed  CAS  Google Scholar 

  32. Naya Y, Mizutani Y, Ochiai A, et al. Preliminary report of association of chronic diseases and erectile dysfunction in middle-aged men in Japan. Urology 2003; 62: 532–6

    Article  PubMed  Google Scholar 

  33. Seyram RM, Albakry A, Ghobish A, et al. Prevalence of erectile dysfunction and its correlates in Egypt: a community-based study. Int J Impot Res 2003; 15: 237–45

    Article  Google Scholar 

  34. Berrada S, Kadri N, Mechakra-Tahiri S, et al. Prevalence of erectile dysfunction and its correlates: a population-based study in Morocco. Int J Impot Res 2003; 15 Suppl. 1: S3–7

    Article  PubMed  Google Scholar 

  35. Walczak MK, Lokhandwala N, Hodge MB, et al. Prevalence of cardiovascular risk factors in erectile dysfunction. J Gend Specif Med 2002; 5: 19–24

    PubMed  Google Scholar 

  36. Müller SC, el-Damanhoury H, Ruth J, et al. Hypertension and impotence. Eur Urol 1991; 19: 29–34

    PubMed  Google Scholar 

  37. Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet 1985; 1: 181–4

    Article  PubMed  CAS  Google Scholar 

  38. Aranda P, Ruilope LM, Calvo C, et al., on behalf of the Sildenafil Study Group. Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study. Am J Hypertens 2004; 17: 139–45

    Article  PubMed  CAS  Google Scholar 

  39. Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319–26

    Article  PubMed  CAS  Google Scholar 

  40. Bansal S. Sexual dysfunction in hypertensive men: a critical review of the literature. Hypertension 1988; 12: 1–10

    Article  PubMed  CAS  Google Scholar 

  41. Bulpitt CJ, Dollery CT, Came S. Changes in symptoms of hypertensive patients after referral to hospital clinic. Br Heart J 1976; 38: 121–8

    Article  PubMed  CAS  Google Scholar 

  42. Bauer GE, Hunyor SN, Baker J, et al. Clinical side effects during antihypertensive therapy: a placebo-controlled double-blind study. Postgrad Med Comm 1981; (Special Report): 49–54

  43. Croog SH, Levine S, Sudilovsky A, et al. Sexual symptoms in hypertensive patients: a clinical trial of antihypertensive medications. Arch Intern Med 1988; 148: 788–94

    Article  PubMed  CAS  Google Scholar 

  44. Fogari R, Zoppi A, Preti P, et al. Sexual activity and plasma testosterone levels in hypertensive males. Am J Hypertens 2002; 15: 217–21

    Article  PubMed  CAS  Google Scholar 

  45. Veterans Administration Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: III. Influence of age, diastolic pressure, and prior cardiovascular disease: further analysis of side effects. Circulation 1972; 45: 991–1004

    Google Scholar 

  46. Perry Jr HM. Treatment of mild hypertension: preliminary results of a two-year feasibility trial. Circ Res 1977; 40 Suppl.1: 1180–7

    Google Scholar 

  47. Bulpitt CJ, Dollery CT. Side effects of hypotensive agents evaluated by a self-administered questionnaire. BMJ 1973; 3: 485–90

    Article  PubMed  CAS  Google Scholar 

  48. Newman RJ, Salerno HR. Sexual dysfunction due to methyldopa [letter]. BMJ 1974; 4: 106

    Article  PubMed  CAS  Google Scholar 

  49. Kolodny RC. Effects of omethyldopa on male sexual function. Sexuality and Disability 1987; 1: 223–7

    Article  Google Scholar 

  50. Rosen RC, Kostis JB, Jeckelis A, et al. Sexual sequelae of antihypertensive drugs: treatment effects on self report and physiological measures in middle-aged male hypertensives. Arch Sex Behav 1994; 23: 135–52

    Article  PubMed  CAS  Google Scholar 

  51. Saunders E, Kong WB. Sexual activity in male hypertensive patients while taking clonidine. Urban Health 1980; 9: 26

    Google Scholar 

  52. Hogan MJ, Wallin JD, Baer RM. Antihypertensive therapy and male sexual dysfunction. Psychosomatics 1981; 21: 234–7

    Google Scholar 

  53. Medical Research Council Working Party on Mild to Moderate Hypertension. Adverse reactions to bendrofluazide and propranolol for treatment of mild hypertension. Lancet 1981; 2: 539–43

    Google Scholar 

  54. Wassertheil-Smoller S, Blaufox MD, Oberman A, et al. Effects of antihypertensives on sexual function and quality of life: the TAIM Study. The TAIM Research Group. Ann Intern Med 1991; 114: 613–20

    CAS  Google Scholar 

  55. Stessman J, Ben-Ishay D. Chlorthalidone-induced impotence. BMJ 1980; 281: 714

    Article  PubMed  CAS  Google Scholar 

  56. Chang SW, Fine R, Siegel D, et al. The impact of diuretic therapy on reported sexual function. Arch Intern Med 1991; 151: 2402–8

    Article  PubMed  CAS  Google Scholar 

  57. Fogari R, Zoppi A, Corradi L, et al. Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. Am J Hypertens 1998; 11: 1244–7

    Article  PubMed  CAS  Google Scholar 

  58. Fogari R, Preti P, Derosa G, et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol 2002; 58: 177–80

    Article  PubMed  CAS  Google Scholar 

  59. Fletcher AE, Chester PC, Hawkins CMA, et al. The effects of verapamil and propranolol on quality of life in hypertension. J Hum Hypertens 1989; 3: 125–30

    PubMed  CAS  Google Scholar 

  60. Suzuki H, Tominaga T, Kumagai H, et al. Effects of first-line antihypertensive agents on sexual function and sex hormones. J Hypertens 1988; 6 Suppl. 4: S649–51

    CAS  Google Scholar 

  61. Rosen RC, Kostis JB, Jekelis AW. Beta-blocker effects on sexual function in normal males. Arch Sex Behav 1988; 17: 241–55

    Article  PubMed  CAS  Google Scholar 

  62. Kostis JB, Rosen RC, Holzer BC, et al. CNS effects of centrally active antihypertensive agents: a prospective placebo-controlled study of sleep, mood-state, cognitive and sexual function in hypertensive males. Psychopharmacology 1990; 102: 163–70

    Article  PubMed  CAS  Google Scholar 

  63. Silvestri A, Galetta P, Cerquetani E, et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J 2003; 24: 1928–32

    Article  PubMed  CAS  Google Scholar 

  64. Kroner BA, Mulligan T, Briggs GC. Effect of frequently prescribed cardiovascular medications on sexual function: a pilot study. Ann Pharmacother 1993; 27: 1329–32

    PubMed  CAS  Google Scholar 

  65. Omvik P, Thaulow E, Herland OB, et al. Double-blind, parallel, comparative study on quality of life during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: a multicenter study. J Hypertens 1993; 11: 103–13

    Article  PubMed  CAS  Google Scholar 

  66. Llisterri Caro JL, Lozano Vidal JV, Aznar Vicente J, et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 2001; 321: 336–41

    Article  Google Scholar 

  67. Fogari R, Preti P, Mugellini A, et al. Different effect of valsartan and lisinopril on sildenafil use in hypertensive men with erectile dysfunction [abstract]. Am J Hypertens 2002; 15: 37A

    Article  Google Scholar 

  68. Fogari R, Preti P, Zoppi A, et al. Effect of valsartan and atenolol on sexual behaviour in hypertensive postmenopausal women. Am J Hypertens 2004; 17: 77–81

    Article  PubMed  CAS  Google Scholar 

  69. Düsing R, Lottermoser K, Mengden T. Compliance with drug therapy: new answers to an old question. Nephrol Dial Transplant 2001; 16: 1317–21

    Article  PubMed  Google Scholar 

  70. Düsing R. Adverse events, compliance, and changes in therapy. Curr Hypertens Rep 2001; 3: 488–92

    Article  PubMed  Google Scholar 

  71. Caro JJ, Speckmann JL, Salas M, et al. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999; 160: 41–6

    PubMed  CAS  Google Scholar 

  72. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998; 20: 671–81

    Article  PubMed  CAS  Google Scholar 

  73. Conlin PR, Gerth W, Fox J, et al. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan vs. other antihypertensive drug classes. Clin Ther 2001; 23: 1999–2010

    CAS  Google Scholar 

  74. Monane M, Bohn RL, Gurwitz JH, et al. The effect of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens 1997; 10: 697–704

    Article  PubMed  CAS  Google Scholar 

  75. Unger T. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program. Am J Cardiol 2003; 91: 28G–34G

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The author was the principal investigator of a study on the subject, which was supported by Novartis Germany (Düsing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Pressure 2003; 12 Suppl. 2: 29–34). He has received honoraria for lectures by several companies relevant to the content of this manuscript, i.e. Boehriner Ingelheim, MSD, Novartis, Pfizer, Schwarz.

Author information

Authors and Affiliations

  1. Universitätsklinikum Bonn, Medizinische Universitäts-Poliklinik, Wilhelmstr. 35–37, Bonn, 53111, Germany

    Rainer Düsing

Authors
  1. Rainer Düsing
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rainer Düsing.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Düsing, R. Sexual Dysfunction in Male Patients with Hypertension. Drugs 65, 773–786 (2005). https://doi.org/10.2165/00003495-200565060-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200565060-00005

Keywords

Search

Navigation